# An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

> clinical trial · VERIFIED · 2026-08-04

Status: RECRUITING · Sponsor: National Human Genome Research Institute (NHGRI) · Condition: Focal Segmental Glomerulosclerosis

- Company: National Human Genome Research Institute (NHGRI)
- Sector: therapeutics
- Primary source: https://clinicaltrials.gov/study/NCT06664814

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.